Original Publication Date: 1 November, 2015
Publication / Source: Melanoma Management
Authors: Chad C Cherington & Alan H Bryce
Historically, treatment options for metastatic melanoma (MM) have been limited, yielding a median overall survival (OS) of 8–10 months and a 5-year survival of less than 10% . These dismal results have been radically improved due to the dramatic advances in immunotherapy for MM. The immunotherapy revolution began with the CTLA-4 inhibitor ipilimumab (Bristol Myers-Squibb, NY, USA), the first medication to show an OS benefit in MM [2,3].